Chen Tianqiao unveils Apodex plan betting on AI self-improvement and drug discovery

According to a November 6, 2026 report by TMTPost, Chen Tianqiao used his latest public talk to disclose the strategy of his newly founded AI company, Apodex, for the first time in a systematic way. The company is committing nearly 10,000 GPUs and a team of 150 scientists to a bet on AI self-evolution and drug discovery, with the stated goal of building the next generation of AI infrastructure for scientific discovery. Chen argued in the talk that the competitive focus of the second half of AI's development is shifting from generation to verification, and that the decisive factor in model capability is not scale but the ability to prove itself correct. Disclosure of the strategy came years after Chen stepped back from frontline operations at Tang Dynasty Internet, the gaming and venture group he founded, to channel his resources into medical research and long-term AI investment. Apodex is the newest vehicle for that agenda. TMTPost's passage does not state a specific launch date for the company, detail which GPUs are being used, or specify which drug discovery programs are being prioritized. The information is based on the single available report so far, and further developments have not yet been documented. No information on the company's funding structure has been made public at this stage.